Mereo BioPharma Group plc
About Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $500.0K
- Net income
- -$41.9M
- Total assets
- $45.9M
- Market cap
- $50.0M
- Operating margin
- -8021.4%
- Net margin
- -8375.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $500.0K
- Operating expenses
- $40.6M
- Operating income
- -$40.1M
- Income tax
- $0
- Net income
- -$41.9M
- EPS (basic)
- $-0.05
- EPS (diluted)
- $-0.05
Balance sheet
- Total assets
- $45.9M
- Current assets
- $45.0M
- Total liabilities
- $5.0M
- Current liabilities
- $4.3M
- Shareholders’ equity
- $40.9M
Cash flow
- Operating cash flow
- -$31.0M
- Investing cash flow
- -$20.0K
- Financing cash flow
- $327.0K
- Net cash flow
- -$28.8M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $50.0M
- EPS (diluted)
- $-0.05
- Shares outstanding
- 166.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 24, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $41.9M in FY2025.
- Revenue declined 95% from FY2023 to FY2025.
- Trading 90% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Mereo BioPharma Group plc.
Write a review
News about Mereo BioPharma Group plc
News & sentiment via Polygon.io
